Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 881 - 900 results of 235,177 for search '(( 10 ((((we decrease) OR (a decrease))) OR (mean decrease)) ) OR ( 2 e decrease ))', query time: 1.99s Refine Results
  1. 881
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 882
    Decreased Ly6G<sup>+</sup> neutrophils in the presence of PLD inhibitors using IF microscopy of lung sections.

    Decreased Ly6G<sup>+</sup> neutrophils in the presence of PLD inhibitors using IF microscopy of lung sections. by Karen M. Henkels (3350273)

    Published 2016
    “…(<b>A,A’,E</b>) Tissues from non-xenographed controls; (<b>B,B’,F</b>) from Xenotransplanted controls with Alzet pumps delivering vehicle; (<b>C,C’,G</b>) Xenotransplanted with Alzet pumps delivering vehicle FIPI or (<b>D,D’,H</b>) VU0155072-2. …”
    Save to List
    Saved in:
  3. 883
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 884
    Decreased proliferation of ErbB2<sup>+</sup>Ph<sup>+</sup>ALL cells is induced by ErbB inhibition.

    Decreased proliferation of ErbB2<sup>+</sup>Ph<sup>+</sup>ALL cells is induced by ErbB inhibition. by Mary E. Irwin (293687)

    Published 2013
    Save to List
    Saved in:
  5. 885
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 886
    The recruitment of MYD88 to TLR2 and IRAK-4 phosphorylation are decreased in β3-integrin–silenced cells.

    The recruitment of MYD88 to TLR2 and IRAK-4 phosphorylation are decreased in β3-integrin–silenced cells. by Tatiana Gianni (499634)

    Published 2014
    Save to List
    Saved in:
  7. 887
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 888
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 889
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 890
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 891
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 892
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 893
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 894
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 895
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 896
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 897
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 898
    GluN2A(D731N) decreases channel open probability.

    GluN2A(D731N) decreases channel open probability. by Kai Gao (120150)

    Published 2017
    “…The di-heteromeric mutant (2A-D731N) and tri-heteromeric receptors with two-copies of the mutant subunit (D731N/D731N) showed a prolonged inhibition rate, reflecting a decreased channel open probability. …”
    Save to List
    Saved in:
  19. 899
    Effect of hydrogen peroxide on cell death in BSO-treated cells.

    Effect of hydrogen peroxide on cell death in BSO-treated cells. by Takeo Edamatsu (4885138)

    Published 2018
    Save to List
    Saved in:
  20. 900
    Effect of exogenous reduced glutathione on cellular vulnerability to hydrogen peroxide in PhS-treated cells.

    Effect of exogenous reduced glutathione on cellular vulnerability to hydrogen peroxide in PhS-treated cells. by Takeo Edamatsu (4885138)

    Published 2018
    Save to List
    Saved in:

Search Tools: